Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma

Phase 4

Completed

• Conditions: Metastatic Renal Cell Cancer
• Interventions: Drug: Sunitinib; Drug: Pazopanib

• Registration Number: NCT02555748
• Lead Sponsor: Institut Claudius Regaud

Brief Summary

This pilot study is an open-label interventional study, prospective, non-comparative, sequential (two stages), national, multicenter study.

Patients starting therapy with sunitinib or pazopanib as standard first line treatment for advanced or metastatic renal cell carcinoma will enter the study in one of the two cohorts (115 patients will be treated by sunitinib and 99 patients will be treated by pazopanib).

The purpose of this study is to examine the feasibility of sunitinib and pazopanib dose individualisation based on therapeutic drug monitoring (TDM) and to assess the benefit of this approach in terms of tolerance and efficacy compared with the current empirical method based only on tolerance observation.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2015-09-04
• Study First Submitted QC: 2015-09-21
• Study First Posted: 2015-09-22
• Study Start: 2015-11-17
• Primary Completion: 2020-01-16
• Study Completion: 2020-01-16
• Status Verified: 2021-01
• Last Update Submitted: 2021-01-11
• Last Update Posted: 2021-01-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 47

Inclusion Criteria

1. Patients starting therapy with sunitinib or pazopanib as standard first line treatment for advanced or metastatic renal cell carcinoma.
2. Measurable tumours as defined by RECIST criteria version 1.1.
3. Age ≥ 18 years old.
4. WHO Performance Status ≤ 2.
5. Life expectancy ≥ 6 months.
6. Adequate cardiac function (baseline Left Ventricular Ejection Fraction (LVEF) ≥ 50% determined by Multiple Gated Acquisition scan (MUGA) or echocardiography) and pulmonary function.
7. Renal function defined as creatinine clearance (Cockcroft and Gault formula) > 30 mL/min.
8. Adequate liver function defined as: total bilirubin ≤ 1.5 x Upper Limit of Normal (ULN); Alanine AminoTansferase (ALAT) and Aspartate AminoTransferase (ASAT) ≤ 2.5 x ULN; Concomitant elevation in bilirubin and ASAT/ALAT above 1.0 x ULN is not allowed.
9. Patients must provide written informed consent prior to performance of study-specific procedures or assessments, and must be willing to comply with treatment and follow-up.
10. Negative pregnancy test for women in childbearing potential.
11. Women of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study (before study entry and until 30 days after the last administration of study treatment).
12. Patients affiliated to a social health insurance.

Exclusion Criteria

1. Patients without any venous access for blood sampling.

2. Hypersensitivity to the active substance or to any of the excipients.

3. History or clinical evidence of central nervous system (CNS) metastases, except for individuals who have previously-treated CNS metastases.

4. Corrected QT interval (QTc) > 480msecs using Bazett's formula.

5. Patients with other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study, such as, but not limited to:

   • Uncontrolled infection.
   • Cardiovascular conditions within the last 6 months such as cardiac angioplasty or stenting, myocardial infarction, unstable angina, coronary artery bypass graft surgery, symptomatic peripheral vascular disease, Class III or IV congestive heart failure, as defined by the New-York Heart Association (NYHA), clinically significant irregular heartbeat requiring medication.
   • Poorly controlled hypertension [defined as systolic blood pressure of ≥140 mmHg or diastolic pressure of ≥90 mmHg).
   • History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or deep venous thrombosis (DVT) within the past 6 months.

   Note: patients with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible.

6. Evidence of active bleeding or bleeding diathesis.

7. Patients being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme cytochrome P450 isoenzyme 3A4 (CYP3A4) within the last 14 days prior to inclusion and/or during the study.

8. Patients already treated with an anticancer treatment in the previous four weeks or patient requiring anticancer treatment during the study (chemotherapy, immunotherapy, hormonotherapy, radiotherapy or surgery).

9. Pregnant or breast-feeding women.

10. Positive diagnostic of HIV, B and C hepatitis.

11. Patients with serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with patient's safety, provision of informed consent, or compliance to study procedures.

12. Patients who has forfeited his/her freedom by administrative or legal award or who is under guardianship.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Sunitinib	Sunitinib	Sunitinib will be administered at the standard dose of 50 mg, once daily during 4 consecutive weeks, followed by a wash-out period of 2 weeks (corresponding to a complete cycle of 6 weeks). During the first stage of the study (Part I), dose adjustment of drug dose will be made according to individual patient tolerance to treatment evaluated by clinical and biological monitoring; During the second stage (Part II), dose modification should also be performed according to individual patient tolerance to treatment evaluated by clinical and biological monitoring ans also by using the new Pharmacokinetic-Pharmacodynamic (PK-PD) Algorithm elaborated during the first part.
Pazopanib	Pazopanib	The daily dose of pazopanib will be the standard dose i.e. 800 mg once a day (2 tablets of 400 mg in one oral administration per day) administered each day, continuously, during the treatment phase (complete cycle will be defined as a 6-week period). During the first stage of the study (Part I), adjustment of drug dose will be made according to individual patient tolerance to treatment evaluated by clinical and biological monitoring; During the second stage of the study (Part II), dose modification should also be performed according to individual patient tolerance to treatment evaluated by clinical and biological monitoring ans also by using the new Pharmacokinetic-Pharmacodynamic (PK-PD) Algorithm elaborated during the first part.

Primary Outcome Measures

Name	Time	Method
Part I: Adverse Events according to NCI toxicity scale (version 4.03)	1.5 years
Part I: Pharmacokinetics - Pazopanib or Sunitinib plasma concentrations	On day 1 and day 15 during cycle 1 and cycle 2 (cycle length is 6 weeks)
Part II: Efficacy - Proportion of patients without progression at 1 year. This corresponds to the number of patients without progression at 1 year among the total number of patients in each group	5.5 years
Part II: Tolerance - Proportion of patients without treatment discontinuation due to adverse event (AE) during the first year.	5.5 years	This corresponds to the number of patients without treatment discontinuation due to AE among the total number of patients in each group.

Secondary Outcome Measures

Name	Time	Method
Part I and II: Objective Response (e.g. Complete or Partial Response)	5.5 years	Objective Response will be defined using RECIST Criteria version 1.1.
Part I and II: Hand-foot syndrome (HFS)	5.5 years	Hand-foot syndrome (HFS) will be evaluated using the HFS-14 questionnaire. This scale specifically developed for patients with HFS is a valid and valuable tool for measuring HFS-related QoL impairment.
Part I and II:- Progression free survival.	5.5 years	Progression free survival is defined as the time from inclusion until progression (RECIST Criteria version 1.1) or death. Patients alive at last follow-up news are censored at this date.
Part I and II: Quality of life using the quality of life questionnaire (QLQ)-C30	5.5 years	Quality of life will be evaluated using the QLQ-C30 questionnaire
Part I and II: Safety according to the classification of the NCI: Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.03.	5.5 years

Trial Locations

Locations (8)

CHU DE BORDEAUX - Hôpital Saint-André; 🇫🇷 Bordeaux, France

Institut Claudius Regaud; 🇫🇷 Toulouse, France

CHU DE LIMOGES - Hôpital Dupuytren; 🇫🇷 Limoges, France

Institut Paoli Calmettes; 🇫🇷 Marseille, France

Institut Bergonie; 🇫🇷 Bordeaux, France

Institut Regional Du Cancer Montpellier; 🇫🇷 Montpellier, France

CH RODEZ; 🇫🇷 Rodez, France

Centre Leon Berard; 🇫🇷 Lyon, France